CD1-MR1 2025
Chairs: Paolo Dellabona & Andrew Chancellor
Sponsored by:
Arovella Therapeutics
Understanding unconventional T cell development to generate an ‘off the shelf’ immunotherapy to treat human diseases (#59)
11:05 AM
MAIT cell activation inhibits tumor growth in the liver (#60)
11:30 AM
Cancer Immunotherapy with CAR-Redirected NKT Cells (#61)
11:55 AM
Design of cytokine engineered invariant Natural Killer T (iNKT) cells for adoptive immunotherapy of cancer (#62)
12:15 PM